Numinus Wellness Earnings Call Transcripts
Fiscal Year 2025
-
Quorum was confirmed and all motions, including director elections, auditor appointment, equity plan, share consolidation, and TSX delisting, were approved. Strategic focus is shifting to infrastructure for psychedelic medicine delivery, with steps underway to regain trading compliance and broaden investor appeal.
Fiscal Year 2024
-
A leader in novel psychiatric therapies, the company is expanding its U.S. operations, focusing on ketamine-assisted therapy, robust clinical trial participation, and a licensing model to help other clinics integrate new treatments. Key catalysts include upcoming M&A activity and clinical trial readouts in the next year.
-
Restructuring and cost-cutting led to reduced losses and cash burn, with revenue declining due to clinic closures. The proposed MedBright AI acquisition aims to drive scalable, high-margin growth in the U.S. mental health sector, with rebranding planned post-close.